Schemes for Chemical & Pharma Cluster Exports

India is the pharmacy of the world — pharma exports have doubled over the last decade, from USD 15.44 billion in FY2014 to USD 31.11 billion in FY2026 — and its chemical industry underpins everything from agrochemicals to dyes to specialty intermediates. But the support architecture for these two sectors is genuinely different from general export promotion.

Most exporters know about RoDTEP and Duty Drawback. Far fewer realise that chemical and pharma manufacturers have access to a second, parallel layer: cluster infrastructure schemes, sector-specific PLI programmes, and R&D funding administered not by DGFT but by the Department of Pharmaceuticals and the Department of Chemicals and Petrochemicals.

This guide maps both layers — what applies to your cluster, what applies to your product, and how they stack.

The Two-Layer Structure

Layer 1 — Horizontal schemes. RoDTEP, Duty Drawback, Advance Authorisation, EPCG, Interest Equalisation. Available to chemical and pharma exporters like everyone else. Covered in our Top 10 Government Schemes Every Indian Exporter Should Know in 2026.

Layer 2 — Sector and cluster schemes. PLI for Bulk Drugs, PLI for Pharmaceuticals, Bulk Drug Parks, PRIP, SPI, PCPIR. These are the ones this guide focuses on.

The two layers are complementary, not alternative. A bulk drug manufacturer in a Bulk Drug Park can draw PLI incentives on production, use Advance Authorisation for duty-free KSM imports, and claim RoDTEP on the export itself.

1. PLI Scheme for Bulk Drugs (KSMs, DIs and APIs)

What it is: A production-linked incentive to rebuild domestic manufacturing of Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients — the inputs where India has been heavily import-dependent.

Outlay and duration: Approved in 2020 with an outlay of ₹6,940 crore, the scheme remains in force till 2028-29.

Traction so far: 48 projects covering 33 drugs have been approved, attracting ₹4,814 crore in investment against an initial commitment of ₹4,322 crore. Domestic production capacity has been created for 26 critical APIs previously imported in significant volumes.

Why it matters for exporters: Bulk drugs that were earlier largely imported, such as Penicillin and Clavulanic Acid, are now being manufactured domestically — and India has started exporting them. That is a new export line that did not exist five years ago.

Administered by: Department of Pharmaceuticals (DoP).

2. PLI Scheme for Pharmaceuticals

What it is: A broader incentive covering higher-value pharmaceutical products, aimed at moving India up the value chain rather than competing purely on generic volume.

Outlay: Approved by Cabinet in February 2021 with an outlay of ₹15,000 crore, covering biopharmaceuticals, complex generic drugs, orphan drugs and patented medicines. 55 companies have been selected, including 22 from the MSME sector.

Export performance: From inception through September 2025, the scheme generated cumulative sales of ₹3,08,408 crore, including ₹1,98,509 crore in exports. Actual investment of ₹40,294 crore exceeded the ₹17,275 crore target by 133%.

Who it suits: Manufacturers with the scale and technical capability to move into complex generics, biosimilars or patented products — not standard generic formulators.

3. Bulk Drug Parks Scheme

What it is: Infrastructure support to create dedicated bulk drug manufacturing clusters with shared facilities — the classic cluster-development model applied to APIs.

How the funding works: Grant-in-aid for Common Infrastructure Facilities up to ₹1,000 crore per park or 70% of project cost, whichever is less. For North Eastern and Hilly States (Himachal Pradesh, Uttarakhand, J&K and Ladakh), assistance rises to 90% of project cost.

Where: Three mega parks in Himachal Pradesh, Gujarat and Andhra Pradesh, offering shared infrastructure such as Common Effluent Treatment Plants (CETPs), solvent recovery systems, power supply and logistics support. The three parks are in various stages of development.

Why a unit inside a park is cheaper to run: Effluent treatment and solvent recovery are the two heaviest fixed costs in API manufacturing. Sharing them across a cluster is often the difference between a viable and unviable project — especially for MSMEs that cannot fund a captive CETP.

4. PRIP — Promotion of Research and Innovation in Pharma MedTech

What it is: Launched with an outlay of ₹5,000 crore to transform India's Pharma MedTech sector from cost-based to innovation-based growth, strengthening research and promoting industry-academia linkage in drug discovery, development and medical devices.

Supporting infrastructure: Seven Centres of Excellence have been set up at NIPERs with a total budgetary outlay of ₹700 crore.

Funding trend: PRIP allocation rose sharply to ₹7.5 billion in FY27, up from ₹2.5 billion in FY26, alongside a roughly 13% year-on-year increase in the Department of Pharmaceuticals budget to ₹59 billion.

Who it suits: Exporters looking beyond commodity generics — those investing in process innovation, complex molecules or device development.

5. Strengthening of Pharmaceutical Industry (SPI)

What it is: A scheme with a total financial outlay of ₹500 crore aimed at supporting existing pharmaceutical clusters and MSMEs across the country to improve productivity, quality and sustainability, and to strengthen existing infrastructure in Pharma MSME clusters.

Implementation period: FY 2020-21 to FY 2025-26.

⚠️ Check current status. The stated implementation window has now closed, though the Department of Expenditure has been requested to permit utilisation of balance funds during an extended period. Confirm with the Department of Pharmaceuticals before building plans around SPI.

Why it matters for MSMEs: SPI is one of the few schemes directly targeting upgradation to Revised Schedule M and WHO-GMP standards — the gate you must pass to export to regulated markets.

6. PCPIR — Petroleum, Chemical and Petrochemical Investment Regions

What it is: A policy introduced in 2007 to address fragmented production, long-distance feedstock transport and heavy reliance on imported chemicals — problems that raised production costs and eroded global competitiveness. The objective is to minimise logistics costs, ensure feedstock availability, induce downstream industries and attract investment.

The main clusters: Dahej (Bharuch district, Gujarat) is the most advanced, covering about 453 sq km with investments exceeding ₹1.28 lakh crore. Its success rests on anchor projects supplying feedstock to downstream industries — most significantly the ONGC Petro-Additions (OPaL) complex, whose dual-feed cracker produces over one million tonnes of ethylene annually plus substantial propylene. Other major regions are Vishakhapatnam–Kakinada (Andhra Pradesh) and Paradeep (Odisha).

The export angle: World-class port infrastructure has made Dahej an important base for petrochemical exports. For a downstream chemical exporter, locating inside a PCPIR means feedstock proximity and port access in one decision.

7. Your Export Promotion Council: Pharmexcil and Chemexcil

Both sectors have dedicated EPCs, and RCMC membership is the gateway to most scheme benefits — including MAI-funded trade fair participation.

Pharmexcil — established in 2004 by the Ministry of Commerce and Industry, covering bulk pharmaceuticals, formulations, biotech products, Indian Systems of Medicine, herbal products, diagnostics and clinical research. Its RCMC is valid for one year and requires an active IEC with an updated profile and a linked Digital Signature or Aadhaar e-signature.

Chemexcil — the Basic Chemicals, Cosmetics and Dyes Export Promotion Council, set up by the Ministry of Commerce & Industry in 1963.

What they actually do for you: Export promotion events and buyer-seller meets, RCMC issuance, market intelligence, regulatory guidance on export procedures and documentation, and representation of exporter concerns before government departments. For chemical exporters specifically, Chemexcil runs frequent destination-regulation briefings — recent sessions have covered Japanese chemical regulations and ASEAN chemical and cosmetics frameworks.

8. RELIEF — Time-Bound Support for West Asia Disruption

Why chemical and pharma exporters should care: The Gulf is a major destination for Indian chemical and pharmaceutical shipments, and this sector was directly hit by the 2026 freight and insurance escalation.

What it is: RELIEF — Resilience & Logistics Intervention for Export Facilitation — is a time-bound intervention under the Export Promotion Mission approved to support Indian exporters affected by extraordinary freight escalation, heightened insurance premia and war-related export risks arising from disruptions in the Gulf and wider West Asia maritime corridor. It was notified via DGFT Notification No. 65/2025-26 dated 19 March 2026, with ECGC designated as the nodal and implementing agency for verification, claim processing, disbursement and monitoring.

The three components: Enhanced export credit risk coverage for existing ECGC-insured exporters (up to 100% loss cover); incentivised ECGC insurance for new shipments (up to 95% loss cover); and reimbursement of up to 50% of additional freight and insurance costs for non-ECGC-insured MSME exporters. The MSME reimbursement is capped at ₹50 lakh per exporter.

Eligible destinations: UAE, Saudi Arabia, Qatar, Oman, Kuwait, Bahrain, Iraq, Iran and Yemen — with Egypt and Jordan added via Notification No. 11/2026-27 dated 17 April 2026.

Deadlines are moving. The original shipment window ran to 15 June 2026, but DGFT has since extended timelines under Component II. Check the latest DGFT notification or your EPC before assuming a window has closed.

Quick Reference: Which Scheme Fits Your Profile?

The Compliance Layer You Cannot Skip

Schemes get you capital. Compliance gets you market access — and for regulated markets it is the binding constraint.

• Revised Schedule M and WHO-GMP are the baseline for exporting to regulated markets. Established manufacturers should run a structured GMP gap assessment against Revised Schedule M, WHO-GMP and applicable export market standards such as FDA 21 CFR and EU GMP to build a prioritised compliance roadmap.
• Data integrity is systemic, not clerical. Manufacturers supplying the US, EU or regulated African markets should treat data integrity as a quality-management priority rather than a documentation activity — investment in training, access controls and audit-trail infrastructure underpins sustained export market access.
• CDSCO governs domestic regulatory approval; destination regulators (USFDA, EMA) govern access to their markets. Both matter.

Frequently Asked Questions

Can I claim PLI and RoDTEP together? They operate on different bases — PLI rewards incremental production and sales, RoDTEP remits embedded taxes on the export shipment — so they are generally complementary. Confirm the specific terms of your PLI agreement, as individual scheme conditions vary.

Is the PLI for Bulk Drugs still open to new applicants? The scheme runs until 2028-29, but application windows for approved project rounds have specific cut-offs and 48 projects have already been approved. Check the current status with the Department of Pharmaceuticals.

Do I need Pharmexcil membership to export pharmaceuticals? Membership itself is not legally compulsory, but the RCMC it issues is required to access many scheme benefits and MAI-supported events, so it is effectively necessary for serious exporters.

What is the difference between a Bulk Drug Park and a PCPIR? Bulk Drug Parks are pharma-specific API clusters under the Department of Pharmaceuticals, with shared CETPs and solvent recovery. PCPIRs are much larger petroleum, chemical and petrochemical investment regions built around feedstock anchors like crackers.

My unit is an MSME — which schemes realistically apply? SPI (subject to current status), Chemexcil or Pharmexcil membership for MAI-supported market access, the Interest Equalisation Scheme for cheaper credit, and the RELIEF MSME reimbursement component if you ship to affected West Asian destinations.

The Bottom Line

Chemical and pharma exporters sit on a deeper support stack than most sectors — but the sector-specific layer is administered by different departments, on different timelines, with different application windows than the DGFT schemes exporters know best. The practical approach: secure your EPC membership first, claim the horizontal schemes on every shipment, and evaluate the sector schemes against your actual manufacturing roadmap rather than applying opportunistically.

Because outlays, windows and eligibility are revised frequently, verify current status with the Department of Pharmaceuticals, the Department of Chemicals and Petrochemicals, DGFT, or your Export Promotion Council before committing capital.

This article is for general information and reflects the position as of July 2026. Scheme outlays, application windows and eligibility criteria are revised periodically — confirm current details with the administering department before acting.